11:20 AM EST, 12/27/2024 (MT Newswires) -- Vaxart ( VXRT ) said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4.6 million in the total estimated ceiling for funding to $460.7 million.

The project agreement in June covered funding for a comparative study to evaluate the company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the US Food and Drug Administration, Vaxart ( VXRT ) said Friday in a regulatory filing.

The amendment boosted the funding allotted to the phase 2b trial by $37.7 million to $134.2 million available for payment, Vaxart ( VXRT ) said.

Advanced Technology International is a consortium management firm funded by the US Department of Health and Human Services' Biomedical Advanced Research and

Development Authority.

Price: 0.66, Change: +0.05, Percent Change: +8.59